# AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

> **NCT04099966** · PHASE2 · RECRUITING · sponsor: **Mitchell Cairo** · enrollment: 20 (estimated)

## Conditions studied

- Acute Leukemia
- Severe Aplastic Anemia
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Kostmann
- Diamond Blackfan Anemia
- Amegakaryocytic Thrombocytopenia
- Sickle Cell Disease
- Beta-Thalassemia

## Interventions

- **DRUG:** alpha beta depletion

## Key facts

- **NCT ID:** NCT04099966
- **Lead sponsor:** Mitchell Cairo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099966, "AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04099966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*